<DOC>
	<DOC>NCT00740129</DOC>
	<brief_summary>The purpose of this study is to demonstrate that patients with Paget's disease of the bone who had responded to zoledronic acid treatment as participants in the core registration studies CZOL446K2304 and CZOL446K2305 and later experienced a relapse can be successfully treated with a 5mg infusion of zoledronic acid.</brief_summary>
	<brief_title>Re-treatment of Patients With Paget's Disease Using Zoledronic Acid</brief_title>
	<detailed_description>Uncontrolled study</detailed_description>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Osteitis Deformans</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Written Informed Consent Patients with Paget's disease randomized to the zoledronic acid arm from the CZOL446K2304 and CZOL446K2305 core studies and who were responders by 6 months Confirmed relapse of Paget's disease of bone (i.e. SAP above ULN, bone scan, worsening clinical symptoms) A patient previously treated with zoledronic acid who relapsed and was retreated with antiresorptive bisphosphonate or calcitonin therapy within the last 12 months Bisphosphonate Hypersensitivity Patients with suspected/proven metastases at retreatment Calculated creatinine clearance &lt;35 mL/min at screening Serum calcium level &lt;2.07 mmol/L at screening Active primary hyperparathyroidism, hyperparathyroidism, hypoparathyroidism or hypothyroidism Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Paget's Disease</keyword>
	<keyword>Zoledronic acid</keyword>
	<keyword>Reclast®/Aclasta®</keyword>
	<keyword>infusion</keyword>
	<keyword>re-treatment</keyword>
	<keyword>re-lapse</keyword>
</DOC>